Biotechnology | CDC | FDA | HIV | Therapeutics
The FDA approved drug to treat infants and children with HIV
On June 12, 2020, the U.S. Food and Drug Administration (FDA) approved Tivicay (dolutegravir) tablets and Tivicay PD…
-
-
Biotechnology | FDA | HIV | Therapeutics
ViiV Healthcare announced FDA approval of the first-ever dispersible tablet formulation of dolutegravir for children living with HIV
On Jun. 12, 2020, ViiV Healthcare, a GSK company, with Pfizer and Shionogi Limited, announced the FDA had…
-
AIM ImmunoTech filed provisional patent application for ose of Ampligen(R) as potential therapy for COVID-19 Induced chronic fatigue
On Jun. 11, 2020, AIM ImmunoTech announced that it had filed a provisional patent application for, among other…
-
Innovation Pharma collaborated with regional biocontainment lab on grant application to research Brilacidin as pan-Coronavirus therapeutic
On Jun. 11, 2020, Innovation Pharma and researchers at a U.S. Regional Biocontainment Laboratory (RBL) announced they are…
-
Regeneron began first clinical trials of anti-viral antibody cocktail REGN-COV2 for treatment and prevention of COVID-19
On Jun. 11, 2020, Regeneron announced announced that Science has accepted for publication two papers describing the creation of…
-
Two science publications highlight potential of REGN-COV2 anti-viral antibody cocktail to protect against SARS-CoV-2 escape mutants
On Jun. 11, 2020, Regeneron announced that Science had accepted for publication two papers describing the creation of…
-
Biotechnology | COVID-19 | Diagnostics | FDA | Therapeutics
InBios received FDA Emergency Use Authorization for COVID-19 antibody test
On Jun. 11, 2020, InBios announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
-
Atossa Therapeutics announced availability of manuscript on results from in vitro testing of COVID-19 drug
On Jun. 11, 2020, Atossa Therapeutics announced that the manuscript of the results from in vitro testing of AT-H201, Atossa’s…
-
Biotechnology | FDA | Medicine | Oncology | Pharmaceutical | Radiology | Therapeutics
FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma
On Jun. 11, 2020, Bristol-Myers Squibb announced that Opdivo ® (nivolumab) was approved by the U.S. Food and…
-
Brain cells can harbor and spread HIV virus to the body
On Jun. 11, 2020, researchers have found that astrocytes, a type of brain cell can harbor HIV and…
-
NIH funded study to evaluate drugs prescribed to children with COVID-19
On Jun. 10, 2020, researchers funded by the National Institutes of Health (NIH) launched an effort to evaluate…
-
COVID-19 mouse model announced to speed search for drugs, vaccines
On Jun. 10, 2020, researchers at Washington University School of Medicine in St. Louis reported they have developed…
-
OraSure received BARDA funding for Coronavirus Antibody ELISA using oral fluid samples
On Jun. 10, 2020, OraSure Technologies announced it had been awarded a $629,217 contract from the Biomedical Advanced…
-
RedHill Biopharma submited COVID-19 clinical trial application for phase 2/3 study with Opaganib in Russia
On Jun. 10, 2020, RedHill Biopharma announced it had submitted a Clinical Trial Application (CTA) with the Ministry…
-
BioCryst’s galidesivir stops Zika viral replication in primate model
On Jun. 10, 2020, BioCryst Pharmaceuticals announced new data published in Science Translational Medicine that show, in a…
-
No link between two ongoing Ebola outbreaks in the Democratic Republic of the Congo
On Jun. 9, 2020, genetic sequence analysis by the Democratic Republic of the Congo’s (DRC) National Institute of…
-
Largest catalog of human genetic diversity released
On Jun. 9, 2020, an international gnomAD team of over 100 scientists released its first set of discoveries…
-
Up to 45 percent of SARS-CoV-2 infections may be asymptomatic, new analysis found
On Jun. 9, 2020, researchers from Scripps report that an extraordinary percentage of people infected by the virus…
-
Immunic announced FDA allowance of its phase 2, CALVID-1 clinical trial of IMU-838 in COVID-19
On Jun. 9, 2020, Immunic announced receipt of regulatory allowance from the FDA to initiate its phase 2,…
-
Two-year PALFORZIA data showed on-going safety and efficacy and continued immunomodulation in patients with peanut allergy
On Jun. 8, 2020, Aimmune Therapeutics announced two-year data that suggested long-term efficacy of daily treatment with PALFORZIA…
-
Lilly announced start of phase 1 study for its second potential COVID-19 antibody treatment
On Jun. 8, 2020, Eli Lilly announced its partner Junshi Biosciences had dosed the first healthy volunteer in…
-
Biotechnology | HIV | NIH | Therapeutics
Just – Evotec Biologics partnered with ABL on development of broadly neutralising antibody against HIV
On Jun. 8, 2020, Evotec announced that its Seattle-based subsidiary Just – Evotec Biologics had entered into an…
-
Emergency COVID-19 measures prevented more than 500 million infections
On Jun. 8, 2020, emergency health measures implemented in six major countries have ‘significantly and substantially slowed’ the…
-
Biotechnology | Diagnostics | Disease | Genomics | NIH | Therapeutics
NIH researchers uncovered genes linked to common recurrent fever n children
On Jun. 8, 2020, researchers at the National Human Genome Research Institute announced they had discovered clues to…
-
Innovent and Roche enter into strategic collaboration to discover and develop cellular therapies and bispecific antibodies
On Jun. 8, 2020, Innovent Biologics announced a strategic research and development collaboration with Roche covering multiple cell…
-
Unique biorepository stores samples from Alberta COVID-19 patients for future research
On Jun. 5, 2020, the Alberta Precision Laboratories (APL) COVID-19 Biorepository was announced to ensure researchers have the…
-
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients
On Jun. 5, 2020, results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK)…
-
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
On Jun. 5, 2020, the Chief Investigators of the randomised evaluation of COVid-19 thERapY (RECOVERY) trial on hydroxychloroquine…
-
Sorrento announced COVIDTRAP(STI-4398) demonstrated in preclinical studies its ability to completely inhibit SARS-CoV-2 viral infection In vitro
On Jun. 5, 2020, Sorrento announced it had completed a preclinical batch of the STI-4398 (COVIDTRAP) protein and…
-
AstraZeneca announced next steps towards broad and equitable access to Oxford Universitys COVID-19 vaccine
On Jun. 4, 2020, AstraZeneca announced the next steps in its commitment to broad and equitable global access…
